Key facts
- This page summarizes Jennifer Lyn Herron's Form 4 filing for ChemoCentryx, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Oct 2022, 19:10.
Jennifer Lyn Herron - 20 Oct 2022 Form 4 Insider Report for ChemoCentryx, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 20 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Oct 2022, 19:10:07 UTC
- Prior SEC filing
- 30 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Susan M. Kanaya, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jennifer Lyn Herron filed Form 4 for ChemoCentryx, Inc. on 24 Oct 2022.
Change
- Previous filing in this sequence was filed on 30 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CCXI
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -17,237
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 20 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jennifer Lyn Herron is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
Footnote F2
(Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.